Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aytu BioScience Confirms Export and Incoming Delivery of COVID-19 IgG/IgM Rapid Tests
April 17, 2020
Since Release
$1.36
-0.14
9.23%
Chinese Officials Confirm China Won't Restrict Exports of Medical Products Needed to Fight Coronavirus
Company in Late-Stage Negotiations to Secure Distribution Agreement for Additional COVID-19 IgG/IgM Rapid Test Which is Approved by China's National Medical Products Administration (NMPA)
ENGLEWOOD, CO / ACCESSWIRE / April 17, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that export and delivery of the Company's incoming COVID-19 rapid tests remains on track as previously announced.
Additionally, the Company is in late-stage negotiations to secure rights to distribute a second COVID-19 IgG/IgM rapid test, which is approved by China's National Medical Products Administration (NMPA).
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Since the Company began taking the fight to COVID-19, we have continued to aggressively search for and evaluate diagnostic tests and other novel technologies that may complement our current product offering and benefit COVID-19 patients. Also, given the nationwide shortage of tests, we believe we are obligated to secure as many additional tests as we can to help with this shortage. To that end, I am excited to say we're in the final stages of securing yet another IgG/IgM antibody rapid test for U.S. distribution. This test is already approved by China's NMPA, is being regularly exported from China, and has strong clinical performance. By securing this additional antibody test, we expect to have an even greater supply to fulfill the substantial demand we're experiencing. We all need to continue to do the very best we can to help COVID-19 patients and those medical professionals for whom they care."
Mr. Disbrow continued, "On March 31, an announcement was made by China's Ministry of Commerce restricting the export of medical materials that have not obtained approval from the NMPA. It is important to note that just yesterday the Associated Press released an article titled, ‘China says no plans to limit export of anti-virus supplies.' The article states: ‘Commerce Ministry spokesman Gao Feng said Beijing has taken steps to speed up customs clearance while ensuring the quality of exported epidemic-prevention goods. Gao said Thursday, ‘China has not and will not restrict the export of epidemic prevention materials.' These statements provide us with confidence and are consistent with the information we continue to receive from our test kit licensor. We remain confident about the timely delivery of the Company's incoming order of COVID-19 IgG/IgM tests," commented Mr. Disbrow.
Mr. Disbrow concluded, "We have received further confirmation that the COVID-19 IgG/IgM Rapid Test manufactured by Zhejiang Orient Gene is in the approval process with NMPA. We remain highly confident in the test's clinical performance as recently demonstrated in a published, third-party peer-reviewed study and believe that the Zhejiang Orient Gene COVID-19 IgG/IgM Rapid Test is a reliable test in detecting COVID-19 antibodies. The independent study demonstrates test accuracy of 98.0% and 94.1% for IgG and IgM, respectively, when using PCR-positive cases as true positives, which we believe establishes strong clinical utility of the test."
The Company will continue to inform our stakeholders about our continuing developments relating to our COVID-19 fight and the progress of the Aytu BioScience business.
Why does Pat list CMR last in the list of technologies?
Why does Martin avoid talking about it?
Why haven't they rolled out the product yet?
Why has this been in development for over 10 years?
Good questions!
Did you send this to the company?
“I got an email today saying they have to relabel all their tests, so now they might not be out until later next week,” she said. “This is the flow. Yesterday, we had all this promise that it might happen in a couple of days, and today, it’s totally different. They’re getting FDA approval right now.”
So, is this a new FDA approval as a diagnostic test?
Pres talking about ease of use of testing.
This is AYTU's strong point!
Is this the same type of test as AYTU?
From StockTwits board:
$OPK All you need do is call OPK. They have the kits. I suggested OPK sue Hindenberg, but it's a waste of money and resources I was told. Just call the company. If you think they're lying then before you call put the phone in the tape record mode. I called Willoughby at Pomerantz. Looks like there is no Mr Willoughby there. LOL Pomeranze sued 5 C-virus companies within 24 hours. LOL LOL LOL
2
1
Bullish
Factinvest
23m
$OPK Wall Street Journal today!
BioReference Laboratories, a unit of Opko Health Inc., expects to start a coronavirus-testing service within days, said Jon Cohen, executive chairman of BioReference.
It expects to be able to handle tests for about 1,000 to 2,000 patients daily, and to expand capacity depending on demand, Dr. Cohen said. BioReference will conduct the tests around the clock at a lab in Elmwood Park, N.J.
LabCorp, Quest and BioReference aren’t collecting specimens at their walk-in patient centers. Dr. Cohen said phlebotomists there are primarily trained to draw blood, and not all are trained to take respiratory samples.
Instead, the commercial labs will use couriers to collect specimens at hospitals and doctor’s offices. Typically, doctors or nurses insert swabs into patients’ noses and mouths to collect fluid, and then place the samples in sterile containers.
The BioReference test will cost $55. LabCorp and Quest haven’t released pricing yet.”
wsj.com/articles/whether-yo...
Does anyone have any details about their test? I can not find anything on their website. Questions:
What is price of test?
What is used as a specimen?
How long does it take?
What is accuracy?
Is it ready to distribute?
I emailed them too.
What is the deal with Nanosys Inc.? Are they selling QDOT displays? Why aren't we?
Have you tried getting in touch with this executive to ask him about it?
So, why hasn't this taken off thus far? What is in this stuff besides hyp?
Slimy looking guy.
Is this ready to come crashing down?
I received this Facebook message today:
"Hi Mike, thank you for your message. Unfortunately, there are many things which are out of our control, such as licensing and approvals that we have submitted and have no choice but to wait for.
In the meantime, we have been working very hard to keep our coffee brand growing and thriving, among other projects. We are also very soon to launch the new e-commerce website that was announced in December."
Trump signs executive order aimed at preventing sales of counterfeit goods from overseas
https://www.yahoo.com/finance/news/trump-signs-executive-order-aimed-232600827.html
Why hasn't Quantum capitalized on this yet?
Any more information?
Thanks!
Royal Canadian Navy (RCN), who will evaluate and learn how to deploy the Platform for personnel and asset protection at ports of call around the world.
Around the world!
We're running!
Not able to open. What did it say?
Thanks!
ElectraMeccanica Unveils the Features of its Production Intent Generation 3 SOLO EV
Download as PDFJanuary 21, 2020
VANCOUVER, British Columbia, Jan. 21, 2020 (GLOBE NEWSWIRE) -- ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles, today announced the final features of its production intent Generation 3, single-seat SOLO EV.
“Since joining the company as CEO in August 2019, our team has been tirelessly focused on testing and validating our pilot production Generation 2 SOLO vehicles in ‘real world’ driving conditions. Similar to any vehicle program, these steps resulted in engineering modifications and upgrades to optimize the driver experience and ensure reliability,” said Paul Rivera, Chief Executive of ElectraMeccanica. “Today, I am pleased to announce the final features of the Generation 3 SOLO design, which will be implemented into commercial production later this year with our strategic contract manufacturing partner in China, Zongshen Industrials Group.”
The Generation 3 SOLO, with an MSRP of $18,500, is a trend-setting all-electric, single-seat vehicle expected to revolutionize the commuting, delivery and shared mobility experience. The vehicle will come standard with an advanced liquid-cooled motor incorporating torque limiting electronic stability control, a wider front steering track, electronic power steering, power brakes, a more robust and rugged look, as well as additional side-impact occupant protection. Beyond these significant occupant safety features, the vehicle will also offer enhanced comfort and driver experience upgrades such as air-conditioning, an improved seat design, a quieter cabin interior, and a more modern technology suite including a more powerful sound system with Bluetooth connectivity.
ElectraMeccanica’s SOLO electric vehicle will first be available in the Los Angeles market in 2020 with other west coast cities to follow later in the year. To be one of the first to own a SOLO, please reserve yours online by visiting www.electrameccanica.com.
Rivera, concluded: “The pending launch of our unrivaled Generation 3 SOLO is a game-changer unlike anything on the road today. This vehicle will define a new category, ‘SOLO Mobility’. We believe that today’s commuters deserve a next-generation vehicle that is not only safe, economical and environmentally friendly, but is also stylish and fun to drive!”
https://investors.electrameccanica.com/press-releases/detail/95/electrameccanica-unveils-the-features-of-its-production
INVO on the move!
https://finance.yahoo.com/news/invo-bioscience-signs-joint-venture-140000291.html
Three new clinics in India.
Does Ed's app even have an advantage at this point?
"According to a May 2019 Ipsos report, close to half (47%) the amount of living expenses among proximity mobile payment users in urban areas of China was spent via third-party mobile payments in Q1 2019. That’s 15 percentage points higher than in Q4 2018. During the same period, the transaction value share of cash dropped from 26% to 19%.
Proximity mobile payments are widely used in offline retail—again, often by a simple QR code scan. Among mobile payment users, some of the most common places for such payments were at supermarkets and convenience stores (62.5%), shopping malls (50.5%) and even street stalls (45.8%).
Mobile payment apps are not merely one-dimensional tools for payment; they now offer other services as well. For example, a popular feature on Alipay and WeChat Pay enables diners to make reservations and prepay for meals before arriving at restaurants.
The activities users conduct on mobile payment services include digital purchases (66.4%), paying bills (52.9%), topping off accounts (51.9%), sending peer-to-peer payments (38.3%) and purchasing online wealth management products (21.2%), according to a July 2018 iiMedia Research survey."
Are you sure you're not talking about Ed Stars?
This is what I have discerned too. I got excited and bought in from the hype with India, then saw the light and sold most. I am still hoping they can come up with something more than promises!
Great info!
Thanks
What's it about?
Thanks
What is this about?
Thanks!
"Licensor is obligated to continual to improve and optimize their patented quantum dot solar cell technology and to achieve a peak solar cell conversion efficiency of 15% on or before the 18th month following execution of this agreement. If licensor does not achieve this target performance within this time frame the licensee will deduct and accrue 10% from the total amount of royalties owing until such time the target performance is achieved. Once the target is achieved the accrued royalties will be paid to licensor."
What was the execution date? 11/2018?
Do we know what their current efficiency is?
Does anyone have a link to the India contract?
Thanks!
Then why are these successful businessmen relying on a used blue jean salesperson to run their company?
Has produced zero retail sales.
Successful DNA Tagging of Leather at One of the World’s Largest Tanneries
Business Wire Business Wire•November 12, 2019
STONY BROOK, N.Y.--(BUSINESS WIRE)--
Applied DNA Sciences to present results of Pilot in Asia at Leather Compliance and Sustainability Conference in NYC this week and the SATRA Sustainable Footwear Forum in Wyndham Way, UK, 5 December
Applied DNA Sciences, Inc. (APDN) (“Applied DNA,” “we,” “our” or the “Company””), a leader in large-scale Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the successful DNA tagging of leather at one of the world’s largest tanneries based in Asia.
The work follows a successful research project undertaken within the UK that demonstrated SigNature® DNA could be successfully used to trace the hide of an animal from a farm to the product in a store. Traceability is essential when supporting claims of sustainability or the humane treatment of the animals. Further work in commercial tanneries by the Applied DNA UK team took place following the research project in other tanneries to identify the most practical ways to use SigNature DNA technology in the leather supply chain. We believe our research identified the most efficient and cost-effective methods to apply DNA at specific points in the leather-tanning process map.
The work recently carried out in Asia was focused on tagging both suede and numerous polyurethane leather finishes in a variety of different colors.
“The results are validation of previous work we carried out and we now look forward to the opportunity to apply our technology for the leather industry to help provide much needed traceability for the various stakeholders,” said Dr. James Hayward, president and CEO, Applied DNA. “We are pleased by the interest shown across the leather industry in offering to leather supply chains.”
On November 13, 2019 at Tapestry headquarters in New York City, MeiLin Wan, Vice President for Textiles at Applied DNA will be speaking about our latest developments in DNA traceability at the “Leather Compliance and Sustainability” conference hosted by Eurofins/ BLC. The Company feels that effective traceability of materials up the supply chain is the best way to manage sustainability risk and mitigate against potential environmental and social challenges.
On Thursday, 5 December 2019, Tony Benson, Managing Director of EMEA for Applied DNA, will also present a Keynote at the “SATRA Sustainable Footwear Forum” in Wyndham Way, UK.
Applied DNA has developed its CertainT® system for marking leather through the leather value chain by using a DNA tag. This molecular-based technology can help protect leather products, brands, entire supply chains, and consumers from theft, counterfeiting, fraud and diversion.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to substantial doubt relating to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, its ability to effectively implement its technology in the leather industry, uncertainties relating to its ability to maintain its NASDAQ listing after December 31, 2019 in light of delisting notices received and its recent hearing, the possibility of failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its ability to penetrate key markets, the uncertainties inherent in research, development, and regulatory approval for Applied DNA’s or its partners’ product candidates, shifting enforcement priorities of U.S. federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
View source version on businesswire.com:
INVO Bioscience Enters New Distribution Agreements in Africa to Commercialize the INVOcell In Vivo Fertilization System
PR Newswire PR Newswire•November 7, 2019
Agreements with commercialization partners support INVO Bioscience's planned worldwide rollout of INVOcell
SARASOTA, Fla., Nov. 7, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced it has entered into commercialization agreements in the continent of Africa, covering Nigeria, Uganda, Sudan and Ethiopia, to distribute the revolutionary INVOcell system. The agreements represent INVO Bioscience's initial entry into the highly populated, yet in our opinion severely underserved infertility markets in Africa. The African commercialization agreements support INVO Bioscience's planned worldwide expansion of INVOcell and follow the recent agreement with Ferring Pharmaceuticals to distribute INVOcell in the United States.
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.
More
According to research, approximately 31% of Nigerian couples fail to conceive a child after 12 months of unprotected sex—a rate at least as high as in the West. Across the continent, infertility is on the rise. Infertility comes with devastating social, cultural, emotional and economic consequences for young couples in Africa. However, access to assisted reproductive services remains a big challenge as traditional IVF treatment is limited in many areas of Africa.
The INVOcell system is a novel fertility treatment that uses a woman's own body as a natural incubator for the incubation of eggs and sperm during fertilization and early embryo development. This cost-effective process has shown comparable pregnancy rates to IVF and in our opinion has the ability to significantly increase patient access. The INVOcell system can eliminate the need for costly infrastructure and overhead associated with IVF, one of the primary hindering factors to fertility treatment in many areas of the continent. Additionally, we believe our unique in vivo fertilization process is a powerful motivator for many patients and in our opinion the only acceptable option available to some patients for religious and cultural reasons.
INVO Bioscience has entered into distribution agreements with G-Systems covering Nigeria, and Quality Medicine covering Uganda, Sudan and Ethiopia. Following standard administrative requirements by each company to begin supplying INVOcell in the country, the Company believes distribution will commence in 2020. Each agreement includes minimum annual purchase requirements. Full terms of the agreement were not disclosed.
Steve Shum, CEO of INVO Bioscience, commented, "One of our key objectives moving forward is the rapid adoption of the INVOcell system across the world by entering into commercialization agreements that make sense for the Company and the particular market they serve. G-Systems and Quality Medicine have long-standing experience in the fertility equipment and services market and are enthusiastic about offering the INVOcell solution to their customer base."
Pressly Ahammed, Director of Business Development for INVO Bioscience, added, "I have had great experience working with the teams at G-Systems and Quality Medicine during my tenure at Cooper Surgical. Both of these companies have a reputation for high quality customer service and are trusted by top medical device companies from around the world. Further, both have a specialized focus within infertility that will serve INVO Bioscience well. We look forward to a long and prosperous relationship."
VRA UPDATE ON PATRIOT ONE
https://www.facebook.com/groups/889952311178139/permalink/1402338413272857/
Repeated emails asking how much hydrogen they are producing:
No reply.
RECONASENSE, PATRIOT ONE, AND SMARTER SECURITY JOIN FORCES TO ADDRESS ACTIVE SHOOTER THREATS
AI-Powered Weapons Detection and Entrance Controls Adapt in Real Time as Active Shooter Situations Unfold
AUSTIN, Texas — Oct. 28, 2019 —ReconaSense, the developer of physical security’s first intelligent access control system, Patriot One Technologies Inc., developer of the PATSCAN™ Multi-Sensor Covert Threat Detection Platform, and Smarter Security, the intelligent entrance controls company, today announced an integrated solution for covert weapons detection and automated lockdown intended to detect and deter potential attacks, and save more lives.
FBI statistics released in April designated 27 shootings in 2018 as active shooter incidents, and 2019 has seen at least 21 mass shootings prior to October 1. Responses to these threats have included armed security guards, armed teachers, padlocked entrances, metal detectors, bag x-ray systems, and mass notification alert systems. However, the ability to detect and delay active assailants’ progress into a building before they fire a shot or inflict harm remains elusive.
The PATSCAN Platform and its sensor components can be covertly deployed to detect visible threats as well as concealed weapons on a body or in a bag. Once detected, onsite security is notified instantly via mobile phone, tablet, or desktop so they can respond quickly and effectively to the situation.
Integrating the solution with ReconaSense takes it one step further. Once the PATSCAN Platform detects a threat, access-controlled doors can be locked down with ReconaSense’s proactive access control system, barring entry to a potential attacker or containing them in a specific area. The integrated solution can capture key details about the location and individual, as well as provide real-time video that is transmitted directly to security personnel and first responders.
“Security teams continue to struggle with how to intelligently automate the covert detection of imminent attacks without also generating alarms for every laptop, smartphone, and metal water bottle that comes through the door,” said Jeff Brown, Chairman of the Board for ReconaSense & CEO of Smarter Security. “This collaboration offers a powerful, AI-driven solution for active threat detection and automatic lockdown that works in any space, reduces false alarms, and continues to learn and adapt to situations in real time.”
How It Works
When a weapon – concealed or not – is detected on a pedestrian, the system immediately locks down specific access-controlled doors and turnstiles
Customer policy determines which lanes to lock or unlock until the situation is remediated.
Once remediated, the doors and turnstiles unlock and resume normal flow of traffic.
Unique Benefits
Real-time & instant lockdown
Discrete and accurate weapon detection
Streamlined pedestrian flow that eliminates redundant queueing
“Working with ReconaSense & Smarter Security has been a terrific experience for our Patriot One team. The mission of all three companies is to provide innovative, top-of-the-line security solutions to help protect people and their communities,” said Martin Cronin, CEO and President of Patriot One. “Integrating our PATSCAN Platform with the ReconaSense unification platform and Smarter Security’s state-of-the-art entry takes us one step closer to stopping these horrific tragedies before they take place.”
New York Showcase
This integrated solution will be on demonstration at the ReconaSense and Smarter Security Showroom on Fifth Avenue in New York City in early December.
Q1 fy2020 ends October 31. Revenue is expected for q1 and will be reported on or before December 15th including some paid trials from q4 of fy2019 according to Cronin.
(according to Facebook group post)
Awesome; and they are using CMR!